EUVIMEDEUVIMED entdecken
Fallbericht

Piperacillin–Tazobactam-Induced Immune Thrombocytopenia: A Case Report

Shangwe Kiliaki iD

Journal of Pharmacy Practice · 2023-04 · 36 (2) · 451-452

DOI: 10.1177/08971900211048140 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Pharmacy Practice, online erschienen am 24.09.2021. Verfasst von Shangwe Kiliaki. Beteiligte Einrichtung: Department of Medicine, Division of Hospital Internal Medicine, 4352Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Purpura, Thrombocytopenic, Idiopathic, Thrombocytopenia. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 2 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug-induced immune thrombocytopenia is an isolated thrombocytopenia caused by accelerated platelet destruction from drug-dependent, platelet-reactive antibodies. Heparin-induced thrombocytopenia is the most common drug-induced immune thrombocytopenia. Common implicated antibiotics for drug-induced immune thrombocytopenia include ceftriaxone, trimethoprim–sulfamethoxazole, vancomycin, and penicillin. The platelet nadir can be less than 20 × 10 (9)/L and typically occurs within 1 to 2 weeks of exposure to the inciting drug. Although rare, drug-induced immune thrombocytopenia can be fatal. Diagnosis is made by excluding other causes of thrombocytopenia. Laboratory testing for drug-dependent antiplatelet antibodies is often helpful but not required. Thrombocytopenia typically improves within 1 to 2 days of drug discontinuation and platelet count returns to normal within a week. Identifying and discontinuing the implicated medication is key to prevention of serious complications. A patient case of drug-induced immune thrombocytopenia is described after initiation of empiric piperacillin–tazobactam for refractory right foot cellulitis in the setting of right fourth toe diabetic ulcer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purpura, Thrombocytopenic, IdiopathicThrombocytopeniaHumansAnti-Bacterial AgentsPiperacillin, Tazobactam Drug CombinationVancomycin

Stichwörter der Autor:innen

drug-induced thrombocytopeniaimmune thrombocytopenialow platelets

Substanzen

Anti-Bacterial AgentsPiperacillin, Tazobactam Drug CombinationVancomycin

Autor:innen und Institutionen

  • Department of Medicine, Division of Hospital Internal Medicine, 4352Mayo Clinic, Rochester, MN, USA.

ORCID-Profile: Shangwe Kiliaki

Zitieren

APA

Kiliaki, S. (2023). Piperacillin–Tazobactam-Induced Immune Thrombocytopenia: A Case Report. Journal of Pharmacy Practice, 36(2), 451-452. https://doi.org/10.1177/08971900211048140

Vancouver

Kiliaki S. Piperacillin–Tazobactam-Induced Immune Thrombocytopenia: A Case Report. Journal of Pharmacy Practice. 2023;36(2):451-452. doi:10.1177/08971900211048140

BibTeX
@article{Kiliaki2023,
  author = {Kiliaki, Shangwe},
  title = {Piperacillin–Tazobactam-Induced Immune Thrombocytopenia: A Case Report},
  journal = {Journal of Pharmacy Practice},
  year = {2023},
  volume = {36},
  number = {2},
  pages = {451--452},
  doi = {10.1177/08971900211048140}
}
Kostenlos starten →